研究报告 Research Report 可选消费 W35 周度趋势解析：全球奢侈品板块触底反弹，A/H 业绩落地主导各子行业表现 Week 35 Discretionary Trends: Global Luxury Sector Bottoms Out and Rebounds, A/H Results Drive Sub-sector Performance [Table_yemei1] 观点聚焦 Investment Focus | 股票名称 | 评级 | 股票名称 | 评级 | | --- | --- | --- | --- | | 耐克 | Outperform 石头科技 | | Outperform | | 美的集团 | Outperform 科沃斯 | | Outperform | | 京东集团 | Outperform 永辉超市 | | Outperform | | 海尔智家 | Outperform 波司登 | | Outperform | | 安踏体育 | Outperform 李宁 | | Outperform | | 格力电器 | Outperform 苏泊尔 | | Outperf ...

Investment Rating - The report maintains an "OUTPERFORM" rating for CSPC Pharmaceutical Group [2]. Core Views - The company's performance in 1H25 showed a revenue of CNY 13.3 billion, a year-on-year decrease of 18.5%, with a focus on licensing deals to enhance profits [14][16]. - The report anticipates that the second quarter of 2025 marked the bottom of the company's performance, with expectations for improvement in the second half of the year [4][16]. Financial Performance Summary - **1H25 Results**: Revenue was CNY 13.3 billion (-18.5% y-o-y), with finished drug revenue at CNY 10.2 billion (-24% y-o-y) and API revenue at CNY 2.1 billion (+12% y-o-y). Gross profit margin (GPM) was 65.6% (-5.9 percentage points) [14][15]. - **2Q25 Results**: Revenue reached CNY 6.3 billion (-14% y-o-y), with finished drug revenue at CNY 4.7 billion (-21% y-o-y). GPM was 64.0% (-6.7 percentage points) [15][16]. - **Net Profit**: Net profit attributable to shareholders was CNY 2.5 billion (-24% y-o-y) in 1H25 and CNY 1.1 billion (-24% y-o-y) in 2Q25 [14][15]. Business Development and Licensing Opportunities - The company is expected to secure three major out-licensing deals totaling over USD 5 billion within the year, with SYS6010 (EGFR ADC) anticipated to be a significant transaction [17][21]. - The report highlights the potential for the oral GLP-1 drug to expand into global markets, tapping into obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) markets [17][21]. Clinical Development Progress - SYS6010 is progressing well in both domestic and international clinical trials, with over 1,000 patients enrolled globally [18][19]. - The management is actively pursuing multiple indications for SYS6010, including breast cancer and gastrointestinal tumors, with clinical trial plans expected to commence soon [18][19]. Valuation and Forecast Adjustments - Revenue forecasts for FY25 and FY26 have been adjusted to CNY 29.4 billion and CNY 31.2 billion, respectively, reflecting the impact of volume-based procurement and negotiations [21]. - The target price is set at HKD 13.11, based on a 2026 P/E ratio of 29.1x and an EPS forecast of HKD 0.45 [21].

Group 1: U.S. Economic Indicators - U.S. manufacturing PMI rose from 49.8 to 53.3, exceeding market expectations of 49.7[8] - New home starts increased by 10.6 percentage points to 12.9%, the highest since December 2023[10] - Existing home sales annualized at 4.01 million units, above the expected 3.92 million[10] Group 2: Market Reactions - U.S. stock indices showed mixed performance, with the S&P 500 up 0.3% and the Nikkei 225 down 1.7%[3] - The 10-year U.S. Treasury yield fell by 7 basis points to 4.26%[3] - The U.S. dollar index decreased by 0.12% to 97.72[3] Group 3: Federal Reserve Policy Outlook - Powell signaled a dovish shift at the Jackson Hole meeting, indicating potential rate cuts in September[1] - The Fed may implement a maximum of two rate cuts within the year due to inflation concerns[1] - The ECB is expected to remain on hold in September, as inflation is no longer a primary focus[1]

Group 1: Currency Appreciation Dynamics - The current appreciation of the RMB is primarily driven by holders of foreign exchange (cross-border capital, foreign trade enterprises), while domestic investors remain cautious, as evidenced by the high "Shanghai gold premium" [1] - The RMB exchange rate has experienced two phases: the first phase from April to June was characterized by a collapse in USD credit, while the second phase in July and August saw a return to the significance of the USD-CNY interest rate differential [6] - The report highlights a persistent "three-price divergence" among the gold purchasing power parity, offshore price, and central bank's middle rate, indicating differing expectations between foreign and domestic investors [10] Group 2: Investor Behavior and Central Bank Management - Foreign investors are more focused on the volatility of USD assets and investment returns, leading to increased demand for RMB assets during the USD credit deterioration [16] - Domestic investors, who are typically currency exchangers, are more sensitive to USD yields, which explains the high "Shanghai gold premium" during the USD credit collapse [20] - The central bank has successfully managed expectations by adjusting its operations in the swap market and guiding the middle rate, which has led to increased optimism among domestic investors [22] - The report anticipates that the central bank's guidance may lead the offshore price to rise to a range of 7.0-7.1 [22]

Investment Rating - The report does not explicitly state an investment rating for Gambol Pet Group, but it indicates that the company's performance is in line with market expectations [2][9]. Core Insights - Gambol Pet Group achieved total operating revenue of RMB 3.22 billion in 1H25, representing a year-on-year increase of 37.7%, with a net profit attributable to shareholders of RMB 380 million, up 22.5% year-on-year [2][9]. - The company's gross margin for 1H25 was 42.8%, a slight increase of 0.7 percentage points year-on-year, indicating improved profitability [2][9]. - The domestic business showed significant growth, with Q2 domestic revenue growing nearly 50% year-on-year, while overseas revenue remained flat [3][10]. - The staple food business remains the core growth driver, accounting for 58.7% of main business revenue, with a gross margin of 46.2% [3][10]. - The self-owned brand business has seen significant growth, particularly through direct sales channels on platforms like Alibaba and Douyin, with direct sales revenue reaching RMB 880 million, up 45.9% year-on-year [3][10]. Financial Performance - In 1H25, the company reported a pre-tax profit of RMB 490 million, up 24.7% year-on-year, and a tax rate of 22.7%, slightly higher than the previous year [2][9]. - The company’s operating cash flow for 1H25 was RMB 350 million, compared to RMB 250 million in the same period last year, indicating improved cash generation [2][9]. Business Segments - The staple food segment generated RMB 1.88 billion in revenue, while the snack segment generated RMB 1.29 billion, showing a slower growth rate compared to staple foods [3][10]. - The health supplements and supplies segment contributed RMB 30 million, accounting for 1.0% of main business revenue [3][10]. Market Position and Strategy - The brands Myfoodie and Fregate maintained strong growth, with Myfoodie’s revenue growing over 40% year-on-year and Fregate’s revenue growing over 120% year-on-year [4][11]. - The company has successfully enhanced its market influence through pan-entertainment brand communication and multi-channel online strategies [4][11]. Investment Projects - The company is progressing well with its fundraising projects, including the expansion of its pet food production base and upgrades to its R&D center and logistics [5][12]. - Cumulative investments in various projects have reached significant milestones, with the pet food production base expansion project already generating benefits [5][12].

Manufacturing PMI Insights - In August 2025, the Manufacturing PMI slightly increased to 49.4%, up by 0.1 percentage points from the previous month[8] - The production index rose to 50.8%, marking a 0.3 percentage point increase, remaining above the critical point for four consecutive months[14] - New orders index slightly increased to 49.5%, up by 0.1 percentage points, but still in the contraction zone[14] Sector Performance - Large enterprises' PMI rose to 50.8%, up by 0.5 percentage points, while medium and small enterprises' PMIs were 48.9% and 46.6%, respectively[13] - High-tech manufacturing and equipment manufacturing PMIs were 51.9% and 50.5%, respectively, indicating relative strength in these sectors[13] Price and Inventory Trends - The main raw materials purchase price index rose to 53.3%, up by 1.8 percentage points, indicating expansion, while the factory price index was at 49.1%, up by 0.8 percentage points[20] - The procurement volume index increased to 50.4%, up by 0.9 percentage points, while the finished goods inventory index decreased by 0.6 percentage points, reflecting improved production-sales coordination[23] Service and Construction Sector Analysis - The service sector business activity index reached 50.5%, up by 0.5 percentage points, driven by summer travel and active capital markets[24] - The construction sector's business activity index fell to 49.1%, down by 1.5 percentage points, with new orders index at 40.6%, down by 2.1 percentage points, indicating a significant seasonal decline[27] Risk Considerations - Real estate demand remains weak, posing a risk to overall economic recovery[4][29]

Consumption Trends - Service consumption is experiencing seasonal cooling, particularly in travel, cinema, and tourism as summer ends[6] - Retail and wholesale volumes for automobiles have decreased, while agricultural product prices have shown seasonal recovery[6] Investment Insights - As of August 30, 2025, the cumulative issuance of special bonds reached CNY 3.26 trillion, with August's issuance at CNY 486.5 billion, indicating insufficient support for infrastructure work[17] - Real estate transactions in 30 cities showed a slight seasonal increase, but overall market remains weak, with land transaction area declining and premium rates dropping to 4.07%[17] Trade and Production - Export volumes and prices are weakening, with a year-on-year growth rate of 12.1% for outbound shipments[26] - Most industries are experiencing a decline in operating rates, particularly PTA, which has dropped to its lowest level since 2021 due to production cuts[28] Inventory and Pricing - Coal, steel, and petrochemical inventories are rising, while cement inventory remains stable[32] - Consumer prices are mixed, with industrial prices generally declining; CPI growth is marginally decreasing, particularly in food and housing sectors[38] Currency and Liquidity - The RMB is appreciating rapidly, with the exchange rate against the USD falling from 7.1823 to 7.1330, influenced by central bank policies and market sentiment[42] - The 10-year government bond yield increased by 5.6 basis points to 1.83%, while the one-year yield decreased slightly[39]

Market Overview - A-shares led global markets with a 0.8% increase, while the Hang Seng Index fell by 1.0%[7] - The US dollar index rose by 0.1%, and the Chinese yuan appreciated by 0.7% against the dollar[7] Economic Indicators - The US Q2 GDP growth was revised up to 3.3%, higher than the initial estimate of 3.0%[15] - The core PCE price index in the US rose by 2.88% year-on-year in July, slightly below the expected 2.89%[15] Consumer Sentiment - The Michigan consumer confidence index in the US dropped to 58.2 from 61.7[25] - Eurozone consumer confidence index fell to -15.5 from -14.7, indicating increased pessimism[30] Employment Data - Initial jobless claims in the US decreased to 229,000, down by 5,000 from the previous week[17] - Personal disposable income in the US grew by 4.6% year-on-year in July, while personal consumption expenditure increased by 4.7%[19] Inflation Expectations - One-year inflation expectations in the US rose to 4.8% from 4.5%[25] - The five-year inflation expectation slightly decreased to 3.5% from 3.4%[25] Policy Outlook - Multiple Federal Reserve officials indicated a potential interest rate cut in September, with expectations of a 25 basis point reduction[36] - The Japanese central bank signaled a more favorable environment for potential interest rate hikes compared to April[38]

Investment Rating - The report maintains an "OUTPERFORM" rating for the company with a target price of HKD 105.80, up from a previous target of HKD 90.10 [2][12]. Core Insights - The company is steadily advancing its five-year strategic plan, with an emphasis on internationalization and domestic commercialization, particularly in oncology and cardiovascular markets [4][19]. - The company reported a significant increase in revenue and profitability, with a net profit of RMB 830 million in 1H25, driven by strong product sales and improved R&D efficiency [3][18]. - The company aims to achieve EBITDA breakeven by 2025 and domestic revenue of RMB 20 billion by 2027, with a focus on advancing multiple assets into global Phase III clinical trials by 2030 [5][20]. Financial Performance - Revenue for 2025 is projected to reach RMB 12.58 billion, representing a 34% year-over-year growth, with net profit expected to turn positive at RMB 1.38 billion [12][27]. - The gross margin is expected to remain strong at around 84% in the coming years, with operating profit anticipated to improve significantly [16][27]. Product Pipeline and R&D - The oncology pipeline includes IBI363, which is positioned as a next-generation IO therapy, with ongoing global Phase III trials for various indications [21][22]. - The cardiovascular and metabolic (CVM) segment is highlighted by masitidutide, which is expected to become a leading product in weight loss and diabetes management, with anticipated approval in 2H25 [24][25]. - The company has a rich pipeline of R&D catalysts, with several key programs expected to yield important data in the near future [26][29].

Investment Focus - Amazon is the top pick due to its leading position in the cloud industry with a global market share of 30%, benefiting from scale effects and stable margin improvements [1] - Google is expected to improve its margins to over 20% by the end of the year, driven by AI and advertising, despite current stock price limitations [1] - Alibaba's cloud revenue reached 334 billion RMB in a single quarter, showcasing strong growth potential in the Chinese market [1] - Arista Networks is positioned to benefit from AI capital expenditures, with expected revenue contribution of at least $750 million from its AI backend switch business in 2025 [1] - Meta is increasing its revenue guidance for Q3 to $47.5-50.5 billion, driven by AI marketing and user growth [1] Semiconductor and Memory - SK Hynix is favored due to recovering downstream inventory and a projected doubling of HBM sales this year, with a target price of KRW 280,555 [2] - Cadence has seen strong growth across its core business lines, with over 50% of advanced node designs adopting its technology [2] - Celestica is expanding its market share in the 400G/800G segment, with a revenue forecast of $11.55 billion for the year [2] - Broadcom is expected to exceed $20.5 billion in ASIC revenue in 2026, driven by new customer acquisitions [2] - AMD is projected to see a higher gross margin from its high-end products, with a target price of $188.77 based on a 28x FY26 EPS [2] Internet and Services - Tencent is recommended for its strong revenue growth and new business opportunities, with a target price increase to $700 [3] - Tencent Music is experiencing growth in non-subscription revenue, which is becoming a new growth driver [3] - New Oriental is positioned well with a diversified income source and high brand recognition, leading to a target price of $74 [4] - JD Health is benefiting from the rapid growth of online drug purchasing and prescription outflow trends, with a recommendation for continued investment [7] Healthcare and Pharmaceuticals - Keren Biotechnology is expected to achieve peak overseas sales of $15-20 billion, with a strong pipeline and cash reserves of over $2 billion [6] - Innovent Biologics is projected to reach a domestic revenue target of 20 billion RMB by 2027, supported by its ADC platforms [6] - WuXi AppTec has raised its revenue growth guidance for 2025 to 13-17%, with a projected adjusted profit of 13.2 billion RMB [7] - Hansoh Pharmaceutical is expected to see significant revenue growth from its innovative drugs, with a focus on international expansion [5]